Copyright
©The Author(s) 2016.
World J Gastroenterol. Dec 28, 2016; 22(48): 10643-10652
Published online Dec 28, 2016. doi: 10.3748/wjg.v22.i48.10643
Published online Dec 28, 2016. doi: 10.3748/wjg.v22.i48.10643
20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75-79 | 80-84 | ≥ 85 yr | |
Comorbid conditions | ||||||||||||||
Peptic ulcer | 3.84% | 4.80% | 4.92% | 5.49% | 7.61% | 8.47% | 10.87% | 12.45% | 14.20% | 15.49% | 17.50% | 16.08% | 13.72% | 9.95% |
Diabetes | 0.31% | 0.49% | 0.96% | 1.76% | 3.27% | 5.68% | 8.78% | 13.17% | 18.18% | 22.04% | 25.48% | 25.96% | 23.55% | 16.13% |
Chronic liver disease | 2.17% | 2.99% | 3.74% | 4.40% | 4.76% | 5.99% | 7.55% | 8.68% | 9.09% | 9.03% | 8.01% | 6.91% | 5.65% | 3.96% |
Chronic renal failure | 0.03% | 0.06% | 0.09% | 0.14% | 0.23% | 0.28% | 0.39% | 0.59% | 0.88% | 1.13% | 1.66% | 1.84% | 1.96% | 1.66% |
Gastroesophageal Reflux disease | 6.02% | 8.34% | 8.88% | 9.92% | 13.22% | 13.63% | 17.18% | 19.11% | 22.11% | 22.85% | 23.93% | 20.94% | 17.29% | 11.43% |
Concomitant drugs1 | ||||||||||||||
Aspirin | 0.03% | 0.08% | 0.13% | 0.42% | 1.15% | 2.65% | 5.66% | 10.21% | 15.55% | 19.84% | 24.26% | 25.57% | 25.15% | 19.66% |
Clopidogrel | 0.01% | 0.01% | 0.03% | 0.09% | 0.27% | 0.56% | 1.10% | 2.13% | 3.66% | 5.18% | 7.23% | 8.59% | 9.41% | 7.19% |
Cilostazol | 0.00% | 0.00% | 0.01% | 0.03% | 0.11% | 0.23% | 0.48% | 0.86% | 1.36% | 1.98% | 2.59% | 3.09% | 2.96% | 2.17% |
NSAIDs | 0.48% | 0.66% | 1.00% | 1.65% | 2.28% | 3.58% | 6.19% | 8.77% | 11.81% | 15.27% | 18.31% | 19.83% | 19.57% | 14.99% |
Steroid | 0.27% | 0.35% | 0.44% | 0.59% | 0.72% | 0.91% | 1.23% | 1.64% | 2.18% | 2.99% | 3.60% | 3.80% | 3.48% | 2.50% |
Anticoagulants2 | 0.01% | 0.01% | 0.03% | 0.04% | 0.06% | 0.09% | 0.15% | 0.23% | 0.32% | 0.47% | 0.68% | 0.88% | 0.68% | 0.46% |
SSRI | 0.16% | 0.17% | 0.15% | 0.21% | 0.24% | 0.29% | 0.38% | 0.41% | 0.59% | 0.92% | 1.23% | 1.57% | 1.88% | 1.41% |
No. of risk factors | ||||||||||||||
≥ 1 | 11.53% | 15.26% | 16.72% | 19.63% | 25.88% | 30.45% | 40.22% | 49.00% | 58.39% | 64.43% | 70.27% | 70.69% | 67.59% | 54.93% |
≥ 2 | 1.66% | 2.42% | 3.23% | 4.36% | 6.59% | 9.35% | 14.79% | 20.87% | 28.01% | 33.92% | 39.74% | 40.03% | 36.67% | 25.34% |
≥ 3 | 0.16% | 0.25% | 0.39% | 0.67% | 1.22% | 2.10% | 3.92% | 6.44% | 10.06% | 13.44% | 17.08% | 16.97% | 15.05% | 8.48% |
No. of risk factors | ||||||||||||||
(After H. pylori prevalence imputation) | ||||||||||||||
≥ 1 | 34.84% | 37.72% | 51.60% | 53.61% | 64.84% | 67.08% | 76.84% | 80.34% | 83.99% | 86.35% | 87.86% | 87.91% | 86.93% | 82.20% |
≥ 2 | 4.24% | 5.79% | 8.93% | 10.81% | 16.85% | 20.48% | 30.34% | 38.05% | 46.72% | 52.90% | 57.54% | 57.88% | 54.60% | 42.92% |
≥ 3 | 0.54% | 0.83% | 1.60% | 2.26% | 4.04% | 5.87% | 10.63% | 15.35% | 21.22% | 26.20% | 30.43% | 30.36% | 27.95% | 18.31% |
- Citation: Kim SH, Yun JM, Chang CB, Piao H, Yu SJ, Shin DW. Prevalence of upper gastrointestinal bleeding risk factors among the general population and osteoarthritis patients. World J Gastroenterol 2016; 22(48): 10643-10652
- URL: https://www.wjgnet.com/1007-9327/full/v22/i48/10643.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i48.10643